Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Relmada Therapeutics Inc RLMD

Biotechnology Drug Manufacturers - Specialty & Generic
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone... see more

Current News (NDAQ:RLMD)

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

GlobeNewswire 5 days ago

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

GlobeNewswire December 3, 2025

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

GlobeNewswire November 13, 2025

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

GlobeNewswire November 7, 2025

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire November 4, 2025

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

GlobeNewswire November 4, 2025

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

GlobeNewswire October 7, 2025

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire September 16, 2025

Relmada Issues Mid-Year CEO Letter to Shareholders

GlobeNewswire September 10, 2025
View More News ››

Opinion & Analysis (NDAQ:RLMD)

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

Streetwise Reports October 16, 2019

Relmada Therapeutics launches pharmaceutical armada against chronic pain and opioid abuse

The Life Sciences Report April 20, 2016
View More Opinion ››

Bullboard Posts (NDAQ:RLMD)

RE:RLMD....POsitive? Share price don't think so

RLMD trading at 27 pesos this a.m....only down 24.75% Selling paper to The Greater Fools via ATM Next announcement will be a RS ; )
Iseneschal - April 29, 2025

RLMD ....ATM financing announcement real soon?

Yep
Iseneschal - April 28, 2025

RLMD....U figure it out! Here is the NR

  Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025   ...
Iseneschal - April 28, 2025

RLMD....POsitive? Share price don't think so

Just sayin ....32 pesos now ....LoL
Iseneschal - April 28, 2025

RLMD.... What's that sound u ask ?

Shareholders bailing out open windows
Iseneschal - April 28, 2025

RLMD 2$+ Cash per Share Trading at 70 CENTS Down Huge should

RLMD Should move back closer to a 1$
10QKing - December 4, 2024
View more Bullboard ››

EnviroGold Global Limited.

EnviroGold Global Limited.

EnviroGold Global Limited is a Canadian headquartered clean technology company with a global vision and a strategic focus ...
View More »

Podcasts